Health
Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
Headline as filed by Medical Xpress.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Medical Xpress | Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs |
About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutation |
0m | medicalxpress.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.